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Levodopa is the gold standard for the treatment of Parkinson’s disease (PD) because of its
outstanding clinical efficacy. However, the majority of patients experience various adverse reac-
tions, including the wearing-off phenomenon, the on-off phenomenon, dyskinesia and psychiatric
symptoms. The response to levodopa depends not only on the intrinsic responsiveness of the pa-
tients, but also on various other important factors including the type of levodopa preparation, its
absorption/metabolism, the blood-brain barrier, age at onset of disease and concomitant use of
anti-parkinsonian drugs. This review summarizes factors which influence the effects of levodopa
in PD. To minimize levodopa-induced adverse reactions and to relieve long-term parkinsonian
symptoms, levodopa therapy should be conducted by taking these factors into consideration.
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